ClinicalTrials.Veeva

Menu

The Role of the Nasal Allergen Provocation Test in Starting and Monitoring Allergen Immunotherapy

U

Universitaire Ziekenhuizen KU Leuven

Status

Enrolling

Conditions

Local Allergic Rhinitis
Perennial Allergic Rhinitis
Seasonal Allergic Rhinitis

Treatments

Drug: AIT
Diagnostic Test: NAPT

Study type

Observational

Funder types

Other

Identifiers

Details and patient eligibility

About

This prospective multicentric academic NAPT study aims to compile a database of all patients who initiate immunotherapy.

The NAPT will take place before, during and after AIT to evaluate the cost and effectiveness of the treatment. The study consists of 4 visits and 2 telephone contacts that are repeated annually for 3 years.

This study will be conducted in 2 hospitals: UZ Leuven and AZ ST. Jan Brugge on the consultation Ear, Nose and Throat Diseases (ENT) and the department of Internal Medicine / Allergology

Enrollment

200 estimated patients

Sex

All

Ages

18 to 60 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age >18 and ≤60 years
  • Persistent or intermittent allergic rhinitis complaints, confirmed by SPT and/of immunocap for the specific IgEs.

OR suspected local allergic rhinitis

  • Patients who start with AIT treatment
  • The patient must be motivated and willing to come to all visits
  • The patient must be able to understand and sign the informed consent

Exclusion criteria

  • Uncontrolled asthma
  • Conditions affecting the functioning of the immune system (eg: immune deficiencies, malignancies, autoimmune diseases)
  • Use of β-blockers, immunosuppressants or ACE inhibitors
  • Hypersensitivity to aluminum hydroxide and/or hypersensitivity to any of the excipients in AIT
  • Anaphylaxis after allergen challenge in the past
  • Acute rhinosinusitis in the last 12 weeks
  • Recent surgery on the nose and/or paranasal sinuses in the last 12 weeks
  • Pregnancy

Trial design

200 participants in 1 patient group

Allergic rhinitis patients
Description:
Patients with persistent or intermittent allergic rhinitis complaints, confirmed by skin prick tests and/or immunocap for specific IgEs, that start with AIT treatment.
Treatment:
Drug: AIT
Diagnostic Test: NAPT

Trial contacts and locations

2

Loading...

Central trial contact

Margot Vandekerckhove; Laura Van Gerven, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems